When differential diagnosis of dementia includes both Alzheimer's disease (AD) and the behavioural variant of frontotemporal dementia (bvFTD), distribution of cerebral glucose metabolism as measured using [ 18 F]-2-fluoro-2-deoxy-D-glucose positron emission tomography ([ 18 F]FDG-PET) may be helpful. One important clue for differentiation is the presence of hypometabolism in the posterior cingulate cortex (PCC), usually associated with AD. PCC hypometabolism however, could also be present in bvFTD. Therefore, the specificity of PCC hypometabolism was examined. Based on visual reading PCC hypometabolism was present in 69-73/81 probable AD patients, in 10-16/33 probable bvFTD patients, and in 0-1/22 cognitive normal (CN) subjects. Findings were validated using a PCC to reference tissue [ 18 F]FDG standard uptake value ratio (SUVr) cut-off, which was derived from the receiver operating characteristic (ROC) separating probable AD from CN, resulting in 9-14/33 bvFTD patients having PCC hypometabolism, depending on the reference tissue used. In conclusion, PCC hypometabolism is not restricted to AD.
INTRODUCTION
Reduced uptake of [ 18 F]-2-fluoro-2-deoxy-D-glucose ([ 18 F]FDG) in the posterior cingulate cortex (PCC) is a characteristic feature of Alzheimer's disease (AD) (Herholz, 2014; Kato et al., 2016; Landau et al., 2011; Minoshima et al., 1997) . However, PCC hypometabolism may not be restricted to AD and can also be seen in other dementias such as the behavioural variant of frontotemporal dementia (bvFTD), which is characterized by most prominent hypometabolism in the frontal lobe (Diehl et al., 2004) . Previous studies reported inconsistent findings regarding involvement of the PCC in bvFTD, and involvement of the PCC mostly coincided with more advanced stages of the disease (Broe et al., 2003; Diehl-Schmid et al., 2007; Ishii et al., 1998; Kato et al., 2016; Whitwell et al., 2004) . Little is known about the prevalence of PCC hypometabolism at time of bvFTD diagnosis, nor about its association with clinical phenotype. The aim of this study was therefore to assess the prevalence of PCC hypometabolism in AD, bvFTD, and cognitive normal (CN) subjects using visual reading. A second objective was to explore associations between PCC standard uptake value ratio (SUVr; using both cerebellum and pons as reference regions) and clinical characteristics.
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METHODS

Subjects
A total of 136 subjects from the Amsterdam dementia cohort were included .
AD subjects (n=81) met clinical criteria for probable AD and had CSF tau/Aβ 1-42 >0.52, implying high likelihood for underlying AD pathology (Duits et al., 2014; McKhann et al., 2011) . BvFTD subjects (n=33) met clinical criteria for probable bvFTD and diagnosis was confirmed by a neurologist specialised in bvFTD (YP) (Rascovsky et al., 2011) . Furthermore, all bvFTD patients had CSF Aβ 1-42 >550pg/mL, implying a low likelihood for underlying amyloid pathology (Mulder et al., 2010) . CN subjects (n=22) performed normally on an extensive neuropsychological test battery, and showed no abnormalities on MRI indicative of underlying neurodegeneration, as evaluated by an experienced neuroradiologist (FB). All CN subjects had CSF tau/Aβ 1-42 <0.52, implying a low likelihood for underlying AD pathology (Duits et al., 2014) . The local Medical Ethics Review Committee approved the study. All subjects provided written informed consent prior to inclusion.
Neuropsychological assessment
A standard neuropsychological test battery was used to assess major cognitive functions ( 
APOE genotype and CSF biomarkers
Collection and analysis of APOE genotype and CSF biomarkers were performed as described previously . For inclusion of bvFTD subjects, the cut-off for normal CSF Aβ 1-42 was set at >550pg/mL. For inclusion of AD patients, the cut-off for abnormal CSF tau/Aβ was set at >0.52, and for CN subjects <0.52 (Duits et al., 2014) . Finally, associations between CSF biomarkers and PCC SUVr were assessed using continuous variables. 
MRI protocol
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PET protocol
Prior to injection of ~185 MBq [ 18 F]FDG, patients were required to rest for 10 minutes with eyes closed and earplugs in a dimly lit room. [ 18 F]FDG PET emission scans were acquired at 45 minutes post injection using either an ECAT EXACT HR+ (Siemens/CTI, Knoxville, TN) or a Gemini TF-64 PET/CT (Philips, Best, The Netherlands) scanner. In addition, in case of the HR+, a 10 minutes transmission scan or, in case of the Gemini, a low dose CT scan was acquired prior to the emission scan to correct emission data for tissue attenuation. Image acquisition, pre-processing and the reconstruction protocol have been described elsewhere (Verfaillie et al., 2015) .
Imaging analysis
T1 weighted MR images were co-registered to corresponding [ 18 F]FDG PET data using the Vinci software package (version 2.56.0). Using PVElab together with the Hammers template, regions of interest (ROI) were delineated on the MRI scans and superimposed onto the dynamic PET scan to generate regional time activity curves (TAC). (Hammers et al., 2002; Svarer et al., 2005) Since the pons is not a standard region in this template, it was delineated manually on the co-registered T1w
MR image using in-house built software in IDL, and superimposed onto the dynamic PET images.
The manual delineation was performed based on voxel intensity differences between the pons and the remaining part of the brainstem on the T1w MR image. Using SPM segmentation, pons white matter volumes were extracted from which a 95% CI of pons white matter volume was calculated for quality insurance of the manual delineation. Outliers were checked on both their delineation and segmentation, and when necessary corrected. PCC SUVr was calculated as PCC to reference region ratio, by dividing the images by the reference region value. For the reference tissue cerebellum grey matter (further referred to as 'cerebellum') and pons white matter (further referred to as 'pons') TACs were assessed separately. training to be nuclear medicine physician. PCC hypometabolism was considered to be present when the PCC (defined using anatomical boundaries that are described elsewhere (Minoshima et al., 1994) ) was isointensesince healthy brain metabolism is associated with highest glucose uptake in the PCC (Loessner et al., 1995) or hypointense compared with other cortical regions by thresholding the SUVr image to identify the area in the brain with the highest activity concentration (Minoshima et al., 1997) .
Statistical analyses
Statistical analyses were performed using SPSS for Windows version 22.0 (IBM Corp. Armonk, NY).
Clinical characteristics were compared between diagnostic groups (AD, bvFTD and CN) using chi- 
RESULTS
Cohort characteristics
Characteristics of the three diagnostic groups are summarised in table I. (Hanley and McNeil, 1983) . Data are presented with 95% confidence intervals. ROC-AUCs were calculated based on continuous SUVr values, with either cerebellum (SUVr-c) or pons (SUVr-p) as reference region. No differences were found when ROC-AUC from pons-normalised data were compared with cerebellum-normalised data using the method by Hanley and McNeil (Hanley and McNeil, 1983) .
Relationship between PCC metabolism and clinical characteristics in diagnostic groups
We performed age, sex, and scanner adjusted linear regression analyses to assess associations 
Relationship between PCC metabolism and clinical characteristics in bvFTD patients
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DISCUSSION
The main finding of this study is that PCC hypometabolism was not restricted to AD, but that it was also present in a substantial part of bvFTD patients based on visual reading and a more data-driven approach. Furthermore, PCC metabolism was positively associated with age and with age at onset of complaints in AD, consistent with an earlier study demonstrating more distinct PCC hypometabolism in early-onset compared with late-onset AD . Within bvFTD, presence of PCC hypometabolism based on visual reading was associated with worse memory performance.
Screening tests for global cognition and dementia severity (i.e. MMSE and CDR) however did not differ from bvFTD patients with normal PCC metabolism. Linear regression analyses revealed that within bvFTD patients with PCC hypometabolism based on visual reading, lower PCC [ 18 F]FDG SUVr was associated with worse memory and visuospatial functioning, as well as with higher scores on the CDR (more severe dementia).
Overall, inter-reader agreement was considered good (κ=0.734). In bvFTD patients only, however, Prevalence of PCC hypometabolism in bvFTD varied using the data-driven approach as well, ranging from 27 to 42%. Prevalence of PCC hypometabolism was highest when the cerebellum was used as reference tissue, coinciding a [ 18 F]FDG SUVr cut-off characterized by higher sensitivity for PCC hypometabolism based on the ROC curve separating AD from CN. Higher ROC classification was found in cerebellum-normalised data compared with pons-normalised data, probably since ponsnormalised data has larger scatter, especially in CN subjects and AD patients. Larger scatter in ponsnormalised data could be the result of relative better preservation of glucose metabolism in the pons compared with cerebellum in AD (Minoshima et al., 1995) .
Several studies have investigated functional and molecular brain imaging characteristics in AD and bvFTD, but to the best of our knowledge, this is the first study investigating the prevalence and clinical characteristics of hypometabolism in the PCC in a large sample of AD and bvFTD patients at
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12 diagnosis. One previous study has investigated PCC hypometabolism in the heterogeneous entity of frontotemporal lobar degeneration, and found hypometabolism in four out of fourteen patients (Womack et al., 2011) . Another study separated a sample of eight bvFTD patients based on the presence or absence of autonoetic consciousness, a complex function including the self-awareness in episodic memory, and found that the four impaired patients had lower glucose uptake in the PCC than the others (Bastin et al., 2012) . Other studies demonstrated presence of PCC hypometabolism in more advanced disease stages in bvFTD (Broe et al., 2003; Ishii et al., 1998) .
A biological explanation for PCC hypometabolism in neurodegenerative diseases might be found in the functional organization of the brain. The PCC is a highly anatomically and functionally connected region in the brain, and an important hub in the default mode network (DMN) (Buckner et al., 2008; Raichle et al., 2001) . AD is characterised by early disruption of the DMN, with prominent involvement of the PCC, whereas bvFTD is most commonly associated with early changes in the salience network (Seeley et al., 2009; Zhou et al., 2010) . During disease progression, more brain regions are found to be involved in both AD and bvFTD, suggesting involvement of multiple networks when neurodegeneration progresses. Possibly, involvement of the PCC in bvFTD at diagnosis is associated with further disease progression, supported by our finding that within the subgroup of bvFTD patients with PCC hypometabolism, lower PCC metabolism was associated with worse memory and visuospatial performance, and with greater disease severity based on the CDR score. The suggestion of an association between PCC involvement and further disease severity is consistent with earlier findings (Broe et al., 2003; Ishii et al., 1998) . We found no differences, however, between global measurements for disease severity or duration of complaints at baseline when we compared bvFTD patients with PCC hypometabolism with bvFTD patients with normal PCC metabolism. Another hypothesis could be that bvFTD is a highly heterogeneous disorder, associated with a subgroup of patients characterised by PCC involvement already early in the disease, and associated with memory impairment, worse visuospatial functioning, and more severe dementia when PCC metabolism is lower. An alternative hypothesis could be that local disruption in the frontotemporal cortex affect connected regions such as the PCC in part of the patients (Buckner et al., 2008) .
Among the limitations of our study are the relatively small sample sizes, particularly in the CN group.
This could have led to less accurate results when the prevalence of PCC metabolism was explored using the PCC [ 18 F]FDG SUVr to define a quantitative cut-off for PCC hypometabolism.
Furthermore, the relative small sample size could have resulted in an underestimation of exploratory analyses investigating PCC metabolism with clinical characteristics.
13 Our findings may have important clinical implications, as [ 18 F]FDG PET is used frequently to differentiate between AD and bvFTD, and especially PCC hypometabolism is commonly considered to be specific for AD. In the differential diagnosis of AD, metabolism of the PCC should be interpreted in the context of different biomarkers, including metabolism of other brain regions andfor exampleamyloid and tau status as well.
In conclusion, PCC hypometabolism was present in almost one third of bvFTD patients and therefore it is not restricted to AD. In AD, younger age and age at onset of complaints was associated with lower PCC metabolism, using CN as reference. In addition, within bvFTD patients with PCC hypometabolism based on visual reading, lower PCC metabolism was associated with worse memory and visuospatial functioning, as well as with higher scores on the CDR (more severe dementia).
15 Ethical approval: All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. 
